Pharmacology of the Phosphate Binder, Lanthanum Carbonate

REFERENCES

• Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3):1179–1187.
   PubMed Web of Science ®Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423–1429.
   PubMedGoogle Scholar
• Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl. 3):1–201.
   PubMed Web of Science ®Google Scholar
• Finn WF. Phosphorus management in end-stage renal disease. Semin Dial. 2005;18(1):8–12.
   PubMed Web of Science ®Google Scholar
• Shinaberger CS, Greenland S, Kopple JD, Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511–1518.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant. 2004;19(Suppl. 1):i19–i24.
   PubMedGoogle Scholar
• Sheikh MS, Maguire JA, Emmett M, Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989; 83(1):66–73.
   PubMed Web of Science ®Google Scholar
• Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55(1):299–307.
   PubMed Web of Science ®Google Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42(1):96–107.
   PubMed Web of Science ®Google Scholar
• Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167–3175.
   PubMed Web of Science ®Google Scholar
• Shigematsu T. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70(5):404–410.
   PubMed Web of Science ®Google Scholar
• Arenas MD, Rebollo P, Malek T, A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010;23(6):683–692.
   PubMed Web of Science ®Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96 (10):2818–2827.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study. Clin Nephrol. 2009;72(4):252–258.
   PubMed Web of Science ®Google Scholar
• Behets GJ, Dams G, Vercauteren SR, Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol. 2004;15(8):2219–2228.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2000. Safety pharmacology studies for human pharmaceuticals S7A. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf. Accessed January 21, 2011.
   Google Scholar
• Vogel H, Hock F, Maas J, Mayer D. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Berlin: Springer-Verlag; 2006.
   Google Scholar
• Nagano N, Miyata S, Obana S, Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2001;16(9):1870–1878.
   PubMed Web of Science ®Google Scholar
• Nagano N, Miyata S, Obana S, Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant. 2003;18(10):2014–2023.
   Google Scholar
• Behets GJ, D'Haese PC, De Broe ME. Gastrointestinal calcium absorption after ingestion of non calcium containing phosphate binders in a healthy rat model [Abstract F-PO1859]. J Am Soc Nephrol. 2009;20:537A.
   Google Scholar
• Evans CH. Biochemistry of the Lanthanides. New York: Plenum Press; 1990.
   Google Scholar
• Damment SJ, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett. 2007;171:69–77.
   PubMed Web of Science ®Google Scholar
• Kato M, Sugihara J, Nakamura T, Muto Y. Electron microscopic study of the blood-brain barrier in rats with brain edema and encephalopathy due to acute hepatic failure. Gastroenterol Jpn. 1989;24(2):135–142.
   Google Scholar
• Xu J, Ling EA. Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J Anat. 1994;184:227–237.
   PubMed Web of Science ®Google Scholar
• Sacchiero R, Berlove D, Brezzani A, Hanus M, Zhorov E, Burke S. Lanthanum deposition in tissues of renal compromised rats fed lanthanum carbonate for 28 days [Abstract F-PO658]. J Am Soc Nephrol. 2003;14:205A.
   Google Scholar
• Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005;67(3):1062–1069.
   PubMed Web of Science ®Google Scholar
• Damment SJ, Cox AG, Secker R. Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? Toxicol Lett. 2009;188(3):223–229.
   Google Scholar
• Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007;71(3):252–259.
   PubMed Web of Science ®Google Scholar
• Meyers FH, Jawetz E, Goldfein A. Gastrointestinal drugs. In: Review of Medical Pharmacology. Los Altos, CA: Lange Medical Publications; 1980:325–331.
   Google Scholar